CYTK
Price
$54.09
Change
-$1.84 (-3.29%)
Updated
Sep 6 closing price
54 days until earnings call
MDGL
Price
$243.89
Change
-$2.11 (-0.86%)
Updated
Sep 6 closing price
60 days until earnings call
Ad is loading...

CYTK vs MDGL

Header iconCYTK vs MDGL Comparison
Open Charts CYTK vs MDGLBanner chart's image
Cytokinetics
Price$54.09
Change-$1.84 (-3.29%)
Volume$1.4M
CapitalizationN/A
Madrigal Pharmaceuticals
Price$243.89
Change-$2.11 (-0.86%)
Volume$222.46K
CapitalizationN/A
View a ticker or compare two or three
CYTK vs MDGL Comparison Chart
Loading...
CYTK
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
CYTK vs. MDGL commentary
Sep 08, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a Hold and MDGL is a Hold.

COMPARISON
Comparison
Sep 08, 2024
Stock price -- (CYTK: $55.98 vs. MDGL: $246.11)
Brand notoriety: CYTK and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 82% vs. MDGL: 70%
Market capitalization -- CYTK: $6.36B vs. MDGL: $5.3B
CYTK [@Biotechnology] is valued at $6.36B. MDGL’s [@Biotechnology] market capitalization is $5.3B. The market cap for tickers in the [@Biotechnology] industry ranges from $584.45B to $0. The average market capitalization across the [@Biotechnology] industry is $2.98B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 1 FA rating(s) are green whileMDGL’s FA Score has 0 green FA rating(s).

  • CYTK’s FA Score: 1 green, 4 red.
  • MDGL’s FA Score: 0 green, 5 red.
According to our system of comparison, CYTK is a better buy in the long-term than MDGL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 5 TA indicator(s) are bullish while MDGL’s TA Score has 5 bullish TA indicator(s).

  • CYTK’s TA Score: 5 bullish, 5 bearish.
  • MDGL’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both CYTK and MDGL are a good buy in the short-term.

Price Growth

CYTK (@Biotechnology) experienced а -2.46% price change this week, while MDGL (@Biotechnology) price change was -1.05% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.71%. For the same industry, the average monthly price growth was +3.67%, and the average quarterly price growth was -3.87%.

Reported Earning Dates

CYTK is expected to report earnings on Oct 31, 2024.

MDGL is expected to report earnings on Nov 06, 2024.

Industries' Descriptions

@Biotechnology (-2.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($6.36B) has a higher market cap than MDGL($5.3B). MDGL YTD gains are higher at: 6.366 vs. CYTK (-32.950). CYTK has higher annual earnings (EBITDA): -459.67M vs. MDGL (-494.77M). MDGL (1.06B) and CYTK (1.06B) have equal amount of cash in the bank . MDGL has less debt than CYTK: MDGL (118M) vs CYTK (790M). MDGL has higher revenues than CYTK: MDGL (14.6M) vs CYTK (3.13M).
CYTKMDGLCYTK / MDGL
Capitalization6.36B5.3B120%
EBITDA-459.67M-494.77M93%
Gain YTD-32.9506.366-518%
P/E RatioN/AN/A-
Revenue3.13M14.6M21%
Total Cash1.06B1.06B100%
Total Debt790M118M669%
FUNDAMENTALS RATINGS
CYTK vs MDGL: Fundamental Ratings
CYTK
MDGL
OUTLOOK RATING
1..100
7260
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
75
Overvalued
PROFIT vs RISK RATING
1..100
4440
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
4854
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDGL's Valuation (75) in the Pharmaceuticals Other industry is in the same range as CYTK (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to CYTK’s over the last 12 months.

MDGL's Profit vs Risk Rating (40) in the Pharmaceuticals Other industry is in the same range as CYTK (44) in the Biotechnology industry. This means that MDGL’s stock grew similarly to CYTK’s over the last 12 months.

MDGL's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as CYTK (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's Price Growth Rating (48) in the Biotechnology industry is in the same range as MDGL (54) in the Pharmaceuticals Other industry. This means that CYTK’s stock grew similarly to MDGL’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for MDGL (100) in the Pharmaceuticals Other industry. This means that CYTK’s stock grew significantly faster than MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTKMDGL
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
82%
Momentum
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
82%
MACD
ODDS (%)
Bearish Trend 3 days ago
80%
Bullish Trend 3 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
79%
Advances
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
78%
Declines
ODDS (%)
Bearish Trend 5 days ago
75%
Bearish Trend 5 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
76%
Aroon
ODDS (%)
Bullish Trend 3 days ago
86%
Bearish Trend 3 days ago
77%
View a ticker or compare two or three
Ad is loading...
CYTK
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
EWT51.570.37
+0.72%
iShares MSCI Taiwan ETF
USL35.970.23
+0.65%
United States 12 Month Oil
ESGB21.670.09
+0.41%
NYLI MacKay ESG Core Plus Bond ETF
VABS24.410.03
+0.11%
Virtus Newfleet ABS/MBS ETF
FSEP44.37-0.04
-0.09%
FT Cboe Vest US Equity Buffer ETF Sep

CYTK and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with TVTX. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then TVTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTK
1D Price
Change %
CYTK100%
+1.99%
TVTX - CYTK
57%
Loosely correlated
-1.19%
VBIVQ - CYTK
44%
Loosely correlated
-11.25%
KRON - CYTK
43%
Loosely correlated
+0.55%
IOVA - CYTK
42%
Loosely correlated
-0.10%
DARE - CYTK
42%
Loosely correlated
-3.90%
More

MDGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with KA. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then KA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
+0.31%
KA - MDGL
62%
Loosely correlated
+8.02%
VXRT - MDGL
61%
Loosely correlated
+2.97%
VBIVQ - MDGL
57%
Loosely correlated
-11.25%
ALXO - MDGL
56%
Loosely correlated
-3.16%
REPL - MDGL
55%
Loosely correlated
+2.59%
More